This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
by Zacks Equity Research
Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.
Select Medical (SEM) Expands Rehabilitation Services in Central PA
by Zacks Equity Research
Select Medical (SEM) and UPMC unveil a 20-bed satellite facility of Helen M. Simpson Rehabilitation Hospital in West Shore, thus enhancing specialized inpatient rehabilitation care in Central Pennsylvania.
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
by Zacks Equity Research
Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
by Zacks Equity Research
The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.
Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
by Zacks Equity Research
Corcept's (CORT) pipeline progress has been encouraging with relacorilant currently under evaluation for Cushing's syndrome. The NDA for relacorilant is expected to be filed in the third quarter.
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
by Zacks Equity Research
Corcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating patients with Cushing's syndrome, meets the primary endpoint in a randomized withdrawal phase.
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter 2024 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
by Zacks Equity Research
Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for April 17th
by Zacks Equity Research
BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
Corcept (CORT) Completes Enrollment in Phase II ALS Study
by Zacks Equity Research
The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
by Zacks Equity Research
The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
by Zacks Equity Research
Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
Why Is United Therapeutics (UTHR) Up 8.9% Since Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
by Zacks Equity Research
Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.
Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024
by Zacks Equity Research
Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance.